The advanced wound care market is attracting an increasing number of competitors and investors seeking a stake in this high-need, high-growth space. But although the number of innovative wound care products is on the rise, this is also a highly diverse market, with some striking differences among various regions of the world in terms of product adoption and standard wound care practices.

When the healing process for chronic wounds like diabetic foot ulcers stalls, something must be done to prevent infection and amputation. Out of Denmark, Reapplix APS has a bedside device for creating a three-layered biological patch out of a patient's own blood, without additives, and within 20 minutes.

With estimated revenues in excess of $5 billion per year worldwide, the advanced wound care market has garnered the attention of both major companies and investors for its tremendous potential. Growth in this market is being driven by the development of new bioactive products that can successfully heal chronic wounds such as diabetic foot ulcers, which are among the most challenging and costly to treat.